ST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) today announced that CBSET, a not-for-profit preclinical research institute dedicated to biomedical research ...

Compliance 360 deg results presented by Dr. Raymond Dattilo show superior outcomes at six months for peripheral arterial disease patients treated with CSI's device. St. Paul, MN & San Francisco, CA ...

JACKSONVILLE, Florida — If you have not heard of peripheral artery disease, you are not alone. While physicians and health organizations have made headway in raising awareness that heart disease is ...

On the heels of STRIDE, one of the first trials to show glucagon-like peptide-1 (GLP-1) receptor agonists can help patients with PAD, a retrospective study of more than 100,000 patients provides more ...

New research from Intermountain Health in Salt Lake City finds that patients diagnosed with peripheral arterial disease (PAD) who also have atrial fibrillation (AFib) face a significantly higher risk ...

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI ®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...